InflaRx (NASDAQ: IFRX) has announced new preclinical data demonstrating low reactive metabolite formation of izicopan in human liver microsomes.
Izicopan is an investigational, orally administered, small molecule inhibitor of the C5a receptor C5aR1 that has shown anti-inflammatory therapeutic effects in several pre-clinical disease models and in human studies.
In a statement, Prof. Renfeng Guo, founder and CSO of InflaRx, commented, “These data provide additional insight into the mechanistic profile of izicopan. We believe that, if supported by clinical data, such properties may contribute to its overall differentiation within the C5aR inhibitor class.”
